Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study.
Abortion
Antiphospholipid antibodies
Antiphospholipid syndrome
Primary prophylaxis
Thrombosis
Journal
Clinical reviews in allergy & immunology
ISSN: 1559-0267
Titre abrégé: Clin Rev Allergy Immunol
Pays: United States
ID NLM: 9504368
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
17
05
2021
pubmed:
4
7
2021
medline:
13
4
2022
entrez:
3
7
2021
Statut:
ppublish
Résumé
The natural history of antiphospholipid antibodies (aPL) carriers is not well-established. The objectives of the present study were (a) to study the probability of developing clinical criteria of antiphospholipid syndrome (APS), (b) to identify potential risk factors for developing thrombosis and/or obstetric complications, (c) to study the association between the antibody profile and development of APS, and (d) to determine the efficacy of primary prophylaxis. We retrospectively analyzed 138 subjects with positive aPL who did not fulfill clinical criteria for APS. The mean follow-up time was 138 ± 63.0 months. Thirteen patients (9.4%) developed thrombosis after an average period of 73.0 ± 48.0 months. Independent risk factors for thrombosis were smoking, hypertension, thrombocytopenia, and triple aPL positivity. Low-dose acetyl salicylic acid did not prevent thrombotic events. A total of 28 obstetric complications were detected in 92 pregnancies. During the follow-up, only two women developed obstetric APS. Prophylactic treatment in pregnant women was associated with a better outcome in the prevention of early abortions. The thrombosis rate in patients with positive aPL who do not meet diagnostic criteria for APS is 0.82/100 patients-year. Smoking, hypertension, thrombocytopenia, and the aPL profile are independent risk factors for the development of thrombosis in aPL carriers. Although the incidence of obstetric complications in this population is high (31.6%), only a few of them meet APS criteria. In these women, prophylactic treatment might be effective in preventing early abortions.
Identifiants
pubmed: 34216367
doi: 10.1007/s12016-021-08862-5
pii: 10.1007/s12016-021-08862-5
pmc: PMC8994711
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-362Informations de copyright
© 2021. The Author(s).
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Rheumatol. 2013 Apr;40(4):425-9
pubmed: 23418380
J Thromb Haemost. 2017 Sep;15(9):1782-1787
pubmed: 28662299
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Ann Rheum Dis. 2011 Jun;70(6):1083-6
pubmed: 21285115
Rheumatology (Oxford). 2014 Feb;53(2):275-84
pubmed: 24097288
Lupus. 2008 Jan;17(1):11-5
pubmed: 18089677
Arthritis Rheum. 2007 Dec 15;57(8):1487-95
pubmed: 18050167
Int J Cardiol. 2019 Sep 1;290:1-6
pubmed: 31133433
Lupus. 2014 Dec;23(14):1468-76
pubmed: 25164304
Arthritis Rheum. 2007 Jul;56(7):2382-91
pubmed: 17599766
Ann Rheum Dis. 2011 Aug;70(8):1517-8
pubmed: 21402561
Curr Rheumatol Rep. 2012 Feb;14(1):64-70
pubmed: 22134845
J Rheumatol. 2006 Nov;33(11):2214-21
pubmed: 17014001
Hum Reprod Update. 2012 Sep-Oct;18(5):474-84
pubmed: 22699010
Int J Cardiol. 2020 Feb 1;300:209-213
pubmed: 31757648
J Rheumatol. 2004 Aug;31(8):1560-7
pubmed: 15290736
Lupus. 2017 Feb;26(2):163-169
pubmed: 27432808
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Immunol Res. 2013 Jul;56(2-3):358-61
pubmed: 23568055
Rheumatology (Oxford). 2013 Sep;52(9):1642-7
pubmed: 23681394
Lancet. 2018 Aug 4;392(10145):387-399
pubmed: 30017552
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Blood. 2011 Oct 27;118(17):4714-8
pubmed: 21765019
Lupus. 2015 Oct;24(11):1135-42
pubmed: 25813871
J Thromb Haemost. 2005 Jun;3(6):1231-8
pubmed: 15946213
Arthritis Rheum. 2012 Jul;64(7):2311-8
pubmed: 22275304
J Thromb Haemost. 2010 Apr;8(4):699-706
pubmed: 20088936
Ann Rheum Dis. 2009 Mar;68(3):397-9
pubmed: 18812393
Semin Arthritis Rheum. 2017 Dec;47(3):397-402
pubmed: 28576307
Am J Med. 1996 May;100(5):530-6
pubmed: 8644765
Lupus. 1998;7(1):3-6
pubmed: 9493141
Med Clin (Barc). 2017 May 10;148(9):394-400
pubmed: 28153433
Arthritis Rheum. 1999 Jul;42(7):1309-11
pubmed: 10403256
Rev Clin Esp. 2008 Mar;208(3):135-7
pubmed: 18275767
Nat Rev Rheumatol. 2011 Jun;7(6):330-9
pubmed: 21556027
Arthritis Rheum. 2001 Jun;44(6):1466-7
pubmed: 11407709
BMJ Evid Based Med. 2018 Jun;23(3):84-86
pubmed: 29650725
Rheumatology (Oxford). 2015 Jan;54(1):134-8
pubmed: 25122726
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002859
pubmed: 15846641